[Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma].
OBJECTIVE
To amplify and express the variable region genes of murine derived anti-idiotypic monoclonal antibody and to develop a new kind of ovarian carcinoma vaccine.


METHODS
mRNA was prepared from murine hybridoma which produces anti-idiotypic antibody against OC125. The heavy and light chain variable region genes (VH and VL) were amplified by polymerase chain reaction (PCR), joined by DNA linker fragments to form single chain FV gene (ScFv), and were ligated into phage mid vector, pCANTAB 5E. The recombinant vector was induced into competent E. coli TG1 cells. The phage displayed recombinant antibodies were detected and identified by enzyme-linked immunosorbent assay (ELISA).


RESULTS
The VH, VL and ScFv genes were 340 bp, 325 bp and 750 bp respectively. Some of the transformed clones expressed engineered anti-idiotypic antibodies, which could specifically bind to the original antibody (OC125).


CONCLUSIONS
Genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody was successfully generated. Clinical application of anti-idiotypic antibody to immunotherapy and to prevention of ovarian carcinoma may be studied.
Zhang
X
X
Gynecological Oncology Center, People's Hospital, Beijing Medical University.
Cui
H
H
Qian
H
H
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000912:Antibodies, Neoplasm / Q000276:immunology*; D003001:Cloning, Molecular; D005260:Female; D005818:Genetic Engineering; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology; D051379:Mice; D010051:Ovarian Neoplasms / Q000276:immunology*; D016133:Polymerase Chain Reaction
D000888:Antibodies, Anti-Idiotypic; D000912:Antibodies, Neoplasm; D007135:Immunoglobulin Variable Region